|
Scientists have been observing for decades an intriguing resemblance between multiple sclerosis (MS), a chronic disease where the immune system of the body attacks the central nervous system (CNS) and can cause neurodegeneration, and a deficiency in vitamin B12, an essential nutrient that supports healthy development and functioning of the CNS.
Similar neurological symptoms, such as numbness or tingling in the hands and feet, vision loss, trouble walking or speaking normally, and cognitive impairment, such as memory issues, are produced by both vitamin B12 (commonly known as cobalamin) insufficiency and multiple sclerosis. Researchers at Sanford Burnham Prebys and partners from other institutions have reported a novel molecular relationship between vitamin B12 and multiple sclerosis (MS) that occurs in astrocytes, which are significant non-neuronal glial cells. The discovery was published online in Cell Reports. The findings by senior study author Jerold Chun, M.D., Ph.D., professor and senior vice president of neuroscience drug discovery, and Yasuyuki Kihara, Ph.D., research associate professor and co-corresponding author, and colleagues suggest new ways to improve the treatment of MS through CNS-B12 supplementation. "The shared molecular binding of the brain's vitamin B12 carrier protein, known as transcobalamin 2 or TCN2, with the FDA-approved MS drug fingolimod provides a mechanistic link between B12 signaling and MS, towards reducing neuroinflammation and possibly neurodegeneration," said Chun. "Augmenting brain B12 with fingolimod or potentially related molecules could enhance both current and future MS therapies." In their paper, the team at Sanford Burnham Prebys, with collaborators at University of Southern California, Juntendo University in Japan, Tokyo University of Pharmacy and Life Sciences and State University of New York, focused on the molecular functioning of FTY720 or fingolimod (Gilenya), a sphingosine 1-phosphate (S1P) receptor modulator that suppresses distribution of T and B immune cells errantly attacking the brains of MS patients. Working with an animal model of MS as well as human post-mortem brains, the researchers found that fingolimod suppresses neuroinflammation by functionally and physically regulating B12 communication pathways, specifically elevating a B12 receptor called CD320 needed to take up and use needed B12 when it is bound to TCN2, which distributes B12 throughout the body, including the CNS. This known process was newly identified for its interactions with fingolimod within astrocytes. Importantly, the relationship was also observed in human MS brains. Of particular note, the researchers reported that lower levels of CD320 or dietary B12 restriction worsened the disease course in an animal model of MS and reduced the therapeutic efficacy of fingolimod, which occurred through a mechanism in which fingolimod hitchhikes by binding to the TCN2-B12 complex, allowing delivery of all to the astrocytes via interactions with CD320, with component losses disrupting the process and worsening disease. These new findings further support to the use of B12 supplementation - especially in terms of delivering the vitamin to astrocytes within the brain - while revealing that fingolimod can correct the impaired astrocyte-B12 pathway in people with MS. The scientists said it is possible that other S1P receptor modulators on the market, such as Mayzent, Zeposia and Ponvory, may access at least parts of this CNS mechanism. The study supports B12 supplementation with S1P receptor modulators with the goal of improving drug efficacy for this class of medicines. The study also opens new avenues on how the B12-TCN2-CD320 pathway is regulated by sphingolipids, specifically sphingosine, a naturally occurring and endogenous structural analog of fingolimod, toward improving future MS therapies, Chun said. "It supports creating brain-targeted B12 formulations. In the future, this mechanism might also extend to novel treatments of other neuroinflammatory and neurodegenerative conditions." (ANI)
|
